Proposal for the Creation of ICD-10 Codes for E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI)

 Executive Summary

This proposal seeks the establishment of specific ICD-10 codes for E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI). The recognition of EVALI with dedicated codes within the ICD-10 classification system is critical for accurate diagnosis, epidemiological tracking, and the development of effective treatment protocols. These codes would also facilitate research into the condition and inform public health strategies aimed at reducing the incidence of EVALI.

Background

EVALI is a recently identified health condition associated with the use of e-cigarette or vaping products. It presents with a variety of pulmonary symptoms ranging from mild to severe, including cough, shortness of breath, and chest pain, often accompanied by gastrointestinal symptoms and fever. The identification and classification of EVALI have been challenging due to the lack of specific diagnostic codes, leading to potential underreporting and variability in treatment approaches.

Proposal Details

1. Creation of ICD-10 Codes: We propose the introduction of new ICD-10 codes under a distinct category for EVALI. This category would include codes that specify the severity, symptoms, and outcomes of the condition. Proposed codes could include:

· EV01: EVALI with predominantly respiratory symptoms

· EV02: EVALI with mixed respiratory and gastrointestinal symptoms

· EV03: EVALI with acute respiratory distress syndrome (ARDS)

· EV04: EVALI with complications requiring mechanical ventilation

1. Clinical Guidelines for Diagnosis and Management: Develop comprehensive clinical guidelines that utilize the new EVALI codes, providing healthcare providers with clear criteria for diagnosis, reporting, and management. These guidelines should emphasize the importance of patient history regarding e-cigarette or vaping product use.

Educational Initiatives: Launch education and awareness programs targeting healthcare providers, patients, and the public about the risks associated with e-cigarette or vaping product use and the potential for EVALI. These programs should include information on recognizing early symptoms and seeking timely medical care.

Research and Surveillance: Encourage research into the causes, mechanisms, and treatments of EVALI, leveraging the new ICD-10 codes for consistent data collection and analysis. Establish surveillance systems to monitor the incidence, prevalence, and outcomes of EVALI, contributing to ongoing public health efforts to mitigate the impact of vaping products.

Benefits

Improved Patient Care: The introduction of specific ICD-10 codes for EVALI will enable healthcare providers to accurately diagnose and manage the condition, potentially improving patient outcomes.

Enhanced Data Collection and Research: Specific codes will facilitate the collection of standardized data on EVALI, supporting research and enabling public health authorities to track trends and identify risk factors associated with vaping product use.

Informed Public Health Strategies: Better data and understanding of EVALI will inform public health strategies and interventions aimed at reducing the use of e-cigarettes and vaping products, particularly among vulnerable populations.

Conclusion

The creation of ICD-10 codes for E-Cigarette or Vaping Product Use-Associated Lung Injury (EVALI) represents an essential step in addressing this emerging public health issue. By providing a mechanism for accurate diagnosis and reporting, these codes will enhance patient care, support research, and inform effective public health strategies to combat the harmful effects of vaping. We strongly advocate for the prompt adoption of these proposed codes to improve health outcomes and safeguard public health.

References

Blount, B. C., Karwowski, M. P., Shields, P. G., Morel-Espinosa, M., Valentin-Blasini, L., Gardner, M., Braselton, M., Brosius, C. R., Caron, K. T., Chambers, D., Corstvet, J., Cowan, E., De Jesus, V. R., Espinosa, P., Fernandez, C., Holder, C., Kuklenyik, Z., Kusovschi, J. D., Newman, C., Reis, G. B., Rees, J., Reese, C., Silva, L., Seyler, T., Song, M. A., Sosnoff, C., Spitzer, C. R., Tevis, D., Wang, L., Watson, C., Wewers, M. D., Xia, B., Tremeau-Bravard, A., Wang, G., & Lung Injury Response Laboratory Working Group. (2019). Evaluation of bronchoalveolar lavage fluid from patients in an outbreak of e-cigarette, or vaping, product use–associated lung injury—10 states, August–October 2019. MMWR. Morbidity and Mortality Weekly Report, 68, 1040-1041.

Ghinai, I., Pray, I. W., Navon, L., O’Laughlin, K., Saathoff-Huber, L., Hoots, B., Kimball, A., Tenforde, M. W., Chevinsky, J. R., Layer, M., Ezike, N. O., Meiman, J., Layden, J. E., & Mikosz, C. A. (2020). Risk factors for e-cigarette, or vaping, product use–associated lung injury (EVALI) among adults who use e-cigarette, or vaping, products—Illinois, July–October 2019. MMWR. Morbidity and Mortality Weekly Report, 68, 1034-1039.

Madison, M. C., Landers, C. T., Gu, B. H., Chang, C. Y., Tung, H. Y., You, R., Hong, M. J., Baghaei, N., Song, L. Z., Porter, P., Putluri, N., Salas, R., Gilbert, B. E., Levental, I., Campen, M. J., Corry, D. B., & Kheradmand, F. (2019). Pulmonary toxicity and the pathophysiology of electronic cigarette, or vaping product, use associated lung injury. Frontiers in Pharmacology, 10, 1619.

Kalininskiy, A., Bach, C. T., Nacca, N. E., Ginsberg, G., Marraffa, J., Navarette, K. A., McGraw, M. D., & Croft, D. P. (2019). E-cigarette, or vaping, product use associated lung injury (EVALI): case series and diagnostic approach. The Lancet Respiratory Medicine, 7(12), 1017-1026.

Krishnasamy, V. P., Hallowell, B. D., Ko, J. Y., Board, A., Hartnett, K. P., Salvatore, P. P., Danielson, M., Kite-Powell, A., Twentyman, E., Kim, L., Cyrus, A., Wallace, M., Melstrom, P., Haag, B. L., King, B. A., Briss, P. A., Mikosz, C. A., & Rose, D. A. (2020). Update: characteristics of a nationwide outbreak of e-cigarette, or vaping, product use–associated lung injury—United States, August 2019–January 2020. MMWR. Morbidity and Mortality Weekly Report, 69, 90-94.